Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | CLPP | Q16740 | 3/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822445 | 0.91 | ALDH1A1 (0.37) | ALDH1A1TSHRL3MBTL1MAPK1DAO | |
| SCHEMBL6700327 | 0.86 | CLPP (0.43) | ALDH1A1CLPPNTRK1POLB | |
| SCHEMBL6822444 | 0.83 | NAMPT (0.40) | ALDH1A1KDM4EMEN1KMT2ANCOA1 | |
| SCHEMBL6700576 | 0.79 | CLPP (0.39) | MAPK1CLPPSOS1PARP1PARP2 | |
| Picolamine SCHEMBL6818745 | 0.78 | S1PR3 (0.40) | ALDH1A1TSHRCLPPKDM4EMEN1 | |
| SCHEMBL6699940 | 0.77 | MAPK1 (0.34) | ALDH1A1MAPK1DAOCLPPSOS1 | |
| SCHEMBL6700986 | 0.77 | MAPK1 (0.36) | ALDH1A1TSHRL3MBTL1MAPK1CLPP | |
| SCHEMBL6699350 | 0.75 | P2RX7 (0.35) | MAPK1 | |
| SCHEMBL6697984 | 0.72 | ALDH1A1 (0.36) | ALDH1A1TSHRL3MBTL1MAPK1P2RY14 | |
| SCHEMBL6700329 | 0.70 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1MAPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | claimed |
| US-20040235169-A1 | Inducible expression of transfected genes | HOWARD HUGHES MEDICAL INSTITUTE | 2004-11-25 | — | — | US | disclosed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030104975-A1 | Cofactor-based screening method for nuclear receptor modulators and related modulators | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM) (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1267171-A1 | Cofactor-based screening method for nuclear receptor modulators | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | ALDH1A1 221/4885TSHR 4387/4885L3MBTL1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.